Implicity builds a manufacturer-agnostic remote cardiac monitoring platform that aggregates transmissions from pacemakers, defibrillators, and implantable loop recorders across major device makers into one clinician workflow. FDA-cleared algorithms including the ILR ECG Analyzer, AF Alert Management, and SignalHF filter device-generated alerts and surface clinically relevant events, and the platform adds automated billing support and research analytics for device clinics.

The company reports monitoring more than 120,000 patients daily across over 250 centers in the United States, France, and Germany. Its nationwide EVIDENCE-RM study of 38,687 defibrillator patients, published in Heart Rhythm, associated platform-based monitoring with a 26 percent reduction in all-cause mortality, and its French reimbursement pathway runs under Article L. 162-52 of the Social Security Code.